Bartosz Hudzik: Better Control, Similar Tolerability With Quadruple Therapy in Resistant Hypertension
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared a post on LinkedIn about a recent article by Stefano Taddei et al, published in European Society of Cardiology:
”Resistant hypertension is often treated as a dosing problem.
But what if it’s actually a strategy problem?
Patients with true resistant hypertension face markedly higher risks of stroke, heart failure, kidney disease, and death — yet many remain on prolonged triple therapy despite uncontrolled BP.
The Phase 3 QUADRO trial challenges that inertia.
Switching patients from standard triple therapy to the first full-dose quadruple single-pill combination (adding bisoprolol) delivered:
- −8 mmHg additional systolic BP reduction in just 8 weeks
- Confirmed improvement on 24-hour ambulatory monitoring
- No serious safety concerns
- A single pill instead of therapeutic escalation by fragmentation
In other words: better control, similar tolerability, potentially better adherence.
If resistant hypertension drives disproportionate cardiovascular risk, should we be escalating faster — and simplifying sooner?”
Title: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial
Authors: Stefano Taddei, Krzysztof Narkiewicz, Stéphanie Bricout-Hennel, Parvoleta Petrova, Cécile Batailler, Roland Asmar
Read the Full Article on European Society of Cardiology․
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 15:54Omar Adwan: Patterns of Anemia
-
Apr 14, 2026, 15:43Webinar on Aplastic Anemia Clinical Case – ASH
-
Apr 14, 2026, 15:42Heghine Khachatryan: Endometriosis Is Not Only a Pain Disorder
-
Apr 14, 2026, 15:36Alisha Tuck: Navigating the First Trimester with Ultrasound and Anticoagulation Management
-
Apr 14, 2026, 15:26Tijjani Balas: The End of ‘Type O Negative’ Shortages? – A New Era in Blood Transfusion
-
Apr 14, 2026, 15:07Carlos Henrique Del Carlo: HFpEF Reimagined as an Adipose Tissue Driven Disease
-
Apr 14, 2026, 15:05Matteo Foschi: ASPERA-R Study Reveals Competing Causes Of Breakthrough Stroke On Anticoagulation
-
Apr 14, 2026, 14:48Samwel Mikaye: From Virchow’s Triad to Prevention of PE in Patients with DVT
-
Apr 14, 2026, 14:43Chokri Ben Lamine: Diamond – Blackfan Anemia and Congenital Dyserythropoietic Anemia Pearls